Next full-series is scheduled to begin January 2020!
Calendar icon Tuesday, April 07, 2020 | 10:30 am - 11:30 am March 10 at 3:00 pm | Online WebEx Meeting
From Bench to Clinic: Development of the 3M-052-Alum Vaccine Adjuvant Formulation
Abstract: For nearly a century, aluminum salts have been the most widely used vaccine adjuvant formulation, with an established history of safety and efficacy. Nevertheless, for extremely challenging disease targets such as tuberculosis or HIV, the adjuvant activity of aluminum salts is not adequate to achieve protective efficacy. This presentation will describe a formulation approach to solving this challenge by developing a lipid-based nanosuspension of a synthetic TLR7/8 ligand (3M-052), that facilitates adsorption to aluminum oxyhydroxide (Alum) via the structural properties of the lipid excipient employed.
- Meeting number (access code): 800 839 784
- Meeting password: dPbp2cXmp88
- Join By Phone: +1-415-655-0001
- Join By Video: firstname.lastname@example.org
- To be added to the meeting email Janet.email@example.com
Special thanks to all of our previous presenters
Raymond E. Olsen
Adjunct Professional Practice Associate Professor,
Department of Animal Dairy and Veterinary Sciences, School of Veterinary Medicine, Utah State University
Adjunct Assistant Professor, Department of Orthopeadics,
University of Utah School of Medicine and VA Bone and Joint Laboratory